ReviewInternational journal of molecular sciences2020
Heparan Sulfate Proteoglycan Signaling in Tumor Microenvironment.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Molecular Insights in Uterine Leiomyosarcoma: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Advances in chemoenzymatic synthesis of glycosaminoglycans and proteoglycans.Current opinion in chemical biology · 2026Review
- Proteoglycans as Molecular Regulators of Bone Metastasis: Extracellular Matrix Remodeling, Tumor-Bone Crosstalk, Dormancy, and Therapeutic Opportunities.Biomolecules · 2026Review
- Tumor promotion or suppression: Revisiting the role of EXT1 and Heparan sulfate.Histology and histopathology · 2026Review
- Recombinant NK1 Protein and LEDs: An Innovative Strategy to Counteract Resistant Staphylococcus pseudintermedius and Pseudomonas aeruginosa Strains.Probiotics and antimicrobial proteins · 2026Article
- Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy.International journal of molecular sciences · 2026Review
- TGF-β-induced epithelial to mesenchymal transition drives proteoglycan binding specificity of HPV-based drug conjugates for cancer cells.Frontiers in oncology · 2026Article
- Simple One-Step Deuterated Peracetylation-MALDI-MS/MS (OSDPM) Strategy for Structural Sequencing of Glycosaminoglycan Oligosaccharides.Analytical chemistry · 2025Article
- XGB-BIF: An XGBoost-Driven Biomarker Identification Framework for Detecting Cancer Using Human Genomic Data.International journal of molecular sciences · 2025Article
- Systematic Evaluation of Isolation Techniques and Freeze-Thaw Effects on Plasma Extracellular Vesicle Heterogeneity and Subpopulation Profiling.Journal of extracellular biology · 2025Article
- A translational perspective of the malignant hematopoietic proteoglycome.Cell & bioscience · 2025Review
- Prognostic significance of HS2ST1 expression in patients with hepatocellular carcinoma.Genes & genomics · 2024Article
- Solid-Phase-Supported Chemoenzymatic Synthesis and Analysis of Chondroitin Sulfate Proteoglycan Glycopeptides.Angewandte Chemie (International ed. in English) · 2024Article
- Epigenetic Targeting of Heparan Sulfate 3-ACS pharmacology & translational science · 2024Article
- Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors.Cellular and molecular life sciences : CMLS · 2024Article
- Dichotomous Effects of Glypican-4 on Cancer Progression and Its Crosstalk with Oncogenes.International journal of molecular sciences · 2024Article
- The exostosin glycosyltransferase 1/STAT3 axis is a driver of breast cancer aggressiveness.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- A bird's-eye view of the biological mechanism and machine learning prediction approaches for cell-penetrating peptides.Frontiers in artificial intelligence · 2024Review
- Targeting heparan sulfate proteoglycans as an effective strategy for inhibiting cancer cell migration and invasiveness compared to heparin.Frontiers in cell and developmental biology · 2024Article
- Investigating the Role of Heparanase in Breast Cancer Development Utilising the MMTV-PyMT Murine Model of Mammary Carcinoma.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In the last few decades, heparan sulfate (HS) proteoglycans (HSPGs) have been an intriguing subject of study for their complex structural characteristics, their finely regulated biosynthetic machinery, and the wide range of functions they perform in living organisms from development to adulthood. From these studies, key roles of HSPGs in tumor initiation and progression have emerged, so that they are currently being explored as potential biomarkers and therapeutic targets for cancers. The multifaceted nature of HSPG structure/activity translates in their capacity to act either as inhibitors or promoters of tumor growth and invasion depending on the tumor type. Deregulation of HSPGs resulting in malignancy may be due to either their abnormal expression levels or changes in their structure and functions as a result of the altered activity of their biosynthetic or remodeling enzymes. Indeed, in the tumor microenvironment, HSPGs undergo structural alterations, through the shedding of proteoglycan ectodomain from the cell surface or the fragmentation and/or desulfation of HS chains, affecting HSPG function with significant impact on the molecular interactions between cancer cells and their microenvironment, and tumor cell behavior. Here, we overview the structural and functional features of HSPGs and their signaling in the tumor environment which contributes to tumorigenesis and cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.